Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Diagnostics
Diagnostics · The big question

Repurposed Cell Slides Show Promise in Diagnosing Rare Tumors

Diagnostic utility of anchored multiplex polymerase chain reaction-based fusion assay on sacrificed cytology slides.

PubMed2 min readAI-assisted summary
Editorial illustration for Diagnostic utility of anchored multiplex polymerase chain reaction-based fusion assay on sacrificed cytology slides.
Editorial illustration

Summary

When doctors try to diagnose certain rare cancers, like those in the salivary glands or soft tissues, they often look for "gene fusions." This happens when two different genes accidentally join together and fuel tumor growth. Traditionally, finding these fusions requires a solid chunk of preserved tumor tissue. However, sometimes doctors only have access to cytology smears, which are simple glass slides with a thin layer of cells spread across them. Until now, it was not completely clear if these simple smear slides could reliably be used for advanced genetic testing.

To find out, researchers tested a technique where they digitally archived these cell slides, then physically scraped the cells off the glass to extract their genetic material. Because the original slide is destroyed in the testing process, this is known as a "sacrificed" smear. The research team looked at a targeted group of 14 sacrificed slides to see if they could successfully pull enough genetic material to run a specialized test called an RNA fusion assay.

The results were highly encouraging. In all 14 cases, the team was able to extract enough genetic material to perform the sequencing. Furthermore, they successfully detected cancer-driving gene fusions in 64 percent of those evaluated cases. Finding these specific genetic markers allowed the doctors to make definitive, accurate diagnoses for various tumors.

Why it matters.

For patients, this research points toward a faster and less invasive path to answers. If doctors can get the genetic clues they need from a simple slide of scraped cells, patients might be spared from undergoing additional surgical biopsies just to secure a larger tissue sample. Being able to pinpoint the exact type of tumor using these repurposed slides means that highly targeted treatments can be chosen earlier.

It is important to view these findings as an early proof of concept. The researchers noted a major limitation in their data: out of more than 8,700 fusion tests performed overall during the study period, only 14 involved these sacrificed direct smears. While achieving a 100 percent success rate for genetic extraction in this small group is a great start, larger studies will be needed to confirm that destroying cell slides for genetic testing is a consistently reliable tool for everyday cancer care.

From the source

The story in numbers.

Cases using sacrificed direct smears
14
Gene fusions detected in direct smears
64%
Total cytology specimen assays
807
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Diagnostics

Routine PSA Tests Likely Save Lives, Updated Study Finds

Prostate cancer screening has long been a subject of debate among medical professionals. Doctors commonly use a blood test called the prostate-specific antigen, or PSA, test to look for early signs of the disease. A massive new review of clinical trials has updated our understanding of how well this test works. The findings suggest that relying on the PSA test alone likely reduces the number of men who die specifically from prostate cancer, and it might even reduce overall death rates compared to not screening at all. Routine screening naturally leads to a spike in prostate cancer diagnoses, particularly cases that are localized, meaning the cancer has not spread beyond the prostate gland. However, catching these early cases appears to have a protective effect later on. The data shows routine screening could potentially reduce the number of aggressive, metastatic cancers that eventually spread to other parts of the body. The researchers also looked at a newer screening approach that combines the traditional PSA blood test with a special protein panel, called a kallikrein test, and an MRI scan. So far, early evidence suggests this advanced combination has little to no impact on the number of cancer diagnoses compared to no screening, though it is still too soon to know exactly how it affects long-term survival rates.

PubMed2 min read
Diagnostics

Current Methods for Diagnosing Brain Trauma in Athletes Fall Short

For years, the medical community has sought ways to identify chronic traumatic encephalopathy, a degenerative brain disease linked to repeated head impacts, in living patients. Doctors currently look for a specific group of symptoms known as traumatic encephalopathy syndrome to estimate if an athlete has underlying brain damage. However, new research suggests this evaluation method is highly unreliable. A recent study published in Nature Medicine reveals that the proposed clinical features used to diagnose this syndrome are poor predictors of actual brain pathology. Simply put, the behavioral and cognitive symptoms doctors look for do not accurately match the physical signs of the disease in the brain. Because these clinical features have such a low predictive value, researchers warn that relying on them carries a significant risk of misdiagnosis. It is worth noting that the initial abstract does not share specific sample sizes, statistical parameters, or patient demographics, making it difficult to quantify exactly how often these errors occur. Still, the core finding points to a major flaw in how doctors currently evaluate former athletes for brain trauma.

Nature Medicine1 min read
Diagnostics

Simple AI Uses DNA to Accurately Classify Dozens of Cancers

Machine learning is often hyped in modern medicine, but highly complex algorithms that look flawless in the lab frequently fail in the real world. To solve this, scientists have developed a new artificial intelligence framework that takes a simpler, more reliable approach to diagnosing cancer. By analyzing DNA methylation, which are chemical tags that attach to DNA and influence how genes behave, researchers created a tool capable of classifying dozens of different cancers and healthy tissues with impressive precision. The research team trained their system using a massive dataset of over 10,000 tissue samples. Surprisingly, they found that a straightforward algorithm called logistic regression actually outperformed highly complex deep neural networks. By looking at 1,208 specific chemical markers on the DNA, their simple model achieved a 90 percent accuracy rate in distinguishing between 54 different healthy and cancerous tissue types. When tested on central nervous system tumors, the tool successfully identified 59 different subtypes with an outstanding 94 percent accuracy. To ensure these results were reliable, the team put their methodology to the test using an independent dataset of over 2,300 samples gathered from 28 different studies. They also introduced a special filtering technique to catch and remove abnormal biological data, which further boosted the model's overall performance and helped prevent artificially inflated success rates.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Repurposed Cell Slides Show Promise in Diagnosing Rare Tumors — Daily Strand